The NEPIC Directory > Quotient Sciences

Quotient Sciences

We are a drug development and manufacturing accelerator, providing integrated services across the entire development pathway for small molecules and peptide drug programs. We cut through silos across a range of drug development capabilities, saving precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.

Our global headquarters is in Nottingham, UK with additional locations in Reading, Alnwick, and Edinburgh, UK; and in the US, in Philadelphia, PA, and Miami, FL. With drug development and clinical testing facilities located in both the US and the UK, our teams work with customers in a flexible way by either designing and delivering fully integrated programs at each stage of the development lifecycle, or by providing support through tailored services in areas including:

·         Drug Substance Synthesis & Manufacturing

·         Formulation Development

·         Clinical Trial Manufacturing

·         Commercial Manufacturing

·         Clinical Pharmacology

·         Data Sciences

·         Bioanalysis and Drug Development Consulting

Latest Posts

Dr. Vanessa Zann: Pharmaceutical Technology Contribution


What is biopharmaceutics and how does it fit into the field of pharmaceutical drug development? Quotient Sciences Dr. Vanessa Zann, Senior Drug Development Consultant speaks with Pharmaceutical Technology. Dr. Zann's article examines biopharmaceutics which looks at the fundamental properties of…

Read more >

Solubility & Bioavailability: Difficult Beasts to Tame – Quotient Sciences Dr. Dolly Jacob, Director of Integrated Development Services speaks with Drug Development & Delivery


Poor solubility is becoming increasingly prevalent in drug pipelines. Infact, across the pharmaceutical industry, about 70 percent of drugs that enter development possess insufficient aqueous solubility for adequate and consistent gastrointestinal absorption. In a recent article with Drug Development &…

Read more >

Quotient Sciences Announces Significant Growth in Workforce at Alnwick, UK, Facility


Quotient Sciences, the drug development and manufacturing accelerator, today announced that it has grown the workforce at its Alnwick, UK, facility by 20% over the past 2 years. The Alnwick site’s growth has been fueled by its attractive location, variety…

Read more >

Evecxia Therapeutics Reports Favorable Data From a Phase 1 SAD/MAD Trial


Evecxia Therapeutics, Inc. announced favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram. The Company further…

Read more >

Quotient Sciences Supports Crinetics Pharmaceuticals with Fully Integrated Pediatric Development and Clinical Testing Program


Crinetics Pharmaceuticals, a pharmaceutical company that develops therapies for rare endocrine diseases, and Quotient Sciences, a drug development and manufacturing accelerator, have announced a partnership to support Crinetics’ CRN04894 pediatric program. The partnership will utilize Quotient Sciences’ unique Translational Pharmaceutics®…

Read more >

Quotient Sciences announces multimillion-pound investment in drug substance manufacturing facility


Quotient Sciences, the drug development and manufacturing accelerator, announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, U.K. The investment will significantly expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over the…

Read more >

Share this

Not a Member? Member Login

Company Contact Details

+44 (0) 1665 608 300

Taylor Drive, Alnwick, Northumberland, NE66 2DH

© Copyright. North East of England Process Industry Cluster (NEPIC) 2015